AI-powered pathology solutions provider Aiosyn has announced the launch of its NephroPath platform.
In partnership with Aiosyn, biopharma companies, contract research organisations (CROs) and researchers will be able to expedite chronic kidney disease (CKD) therapy development using quantitative insights that are provided through Nephropath’s Kidney Image Analysis Services.
Go deeper with GlobalData
The platform provides a detailed evaluation of histological biomarkers in kidney biopsies, enhancing the speed of drug development studies.
Utilising computational pathology algorithms, it can segment main tissue classes and quantify interstitial fibrosis, offering precise localisation and quantification of glomeruli.
The company said that the technology addresses the limitations of existing semi-quantitative scoring systems, which are prone to observer variability and often rely on subregions of the kidney.
See Also:
NephroPath’s AI-based quantification delivers reproducible and consistent results, compared to traditional human reading methods. The platform is also pivotal for discovering new CKD biomarkers.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAiosyn CEO Patrick de Boer said: “Using Aiosyn’s NephroPath platform we provide researchers with a new and powerful technique to complement the CKD drug development toolbox.”
The company provides whole kidney quantification and custom kidney analyses through the Kidney Image Analysis Services.
Slide data-derived data-rich analysis offers per-slide tissue quantifications and detailed characterisation of a dataset.
Findings such as biomarker scores and visual results are delivered in a comprehensive image analysis report.
Aiosyn’s platform has already proven its effectiveness in a preclinical study with a CRO. The NephroPath platform successfully segmented kidney tissue classes and quantified glomerulosclerosis and tubular damage in whole rat kidneys.
The study found a positive correlation between the scores and kidney damage, with results to be presented at the CKD Summit in Boston, US.
Last year, Aiosyn launched a new AI kidney suite for renal disease research. This new platform enables biopharma and research organisations to analyse kidney structures and quantify lesions that affect kidney health.
